Search

Your search keyword '"Christophersen I"' showing total 37 results
Start Over Author "Christophersen I"
37 results on '"Christophersen I"'

3. Stroke rates in non-anticoagulated individuals with and without atrial fibrillation and one non-sex CHA2DS2-VASc risk factor: a nationwide registry-based cohort (Atrial Fibrillation in Norway – AFNOR)

Author

Anjum, M, primary, Ariansen, I, additional, Hjellvik, V, additional, Kjerpeseth, L J, additional, Selmer, R, additional, Skovlund, E, additional, Ellekjaer, H, additional, Christophersen, I E, additional, Myrstad, M, additional, Tveit, A, additional, and Berge, T, additional

Published
2022
Full Text
View/download PDF

5. Integration of Scandinavian genetic data with UK biobank data implicates the RBM20 gene with atrial fibrillation pathogenesis

Author

Vad, O. B., Angeli, E., Liss, M., Ahlberg, G., Andreasen, L., Christophersen, I. E., Tveit, A., Haunsoe, S., Svendsen, J. H., Lundegaard, P. R., Gotthardt, M., Olesen, M. S., Vad, O. B., Angeli, E., Liss, M., Ahlberg, G., Andreasen, L., Christophersen, I. E., Tveit, A., Haunsoe, S., Svendsen, J. H., Lundegaard, P. R., Gotthardt, M., and Olesen, M. S.

Published
2021

6. Time trends in incidence rates of atrial fibrillation-related strokes in Norway 2001–2014: a nationwide analysis using data from the cardiovascular disease in Norway (CVDNOR) project

Author

Ariansen, I, primary, Igland, J, additional, Anjum, M, additional, Kjerpeseth, L.J, additional, Selmer, R, additional, Ellekjaer, H, additional, Kalstoe, S, additional, Christophersen, I, additional, Myrstad, M, additional, Ihle-Hansen, H, additional, Tveit, A, additional, Mortensen, L.H, additional, Tell, G.S, additional, and Berge, T, additional

Published
2020
Full Text
View/download PDF

11. Screening for Atrial Fibrillation

Author

Naik, N, Moran, P, Mcmanus, D, Matsumoto, K, Marzona, I, Martinek, M, Mant, J, Ma, C, Løchen, Ml, Kollios, G, Kim, Yh, Keane, K, Kaab, S, Johnson, L, Jackson, R, Heidbuchel, H, Sinner, M, Bernard, Anne, Schilling, R, Babuty, Dominique, Savalieva, I, Angoulvant, Denis, Rudd, A, Clementy, Nicolas, Ribeiro, A, Bernard, Louis, Reidpath, D, Bourguignon, Thierry, Prabhakaran, D, Pericart, Lauriane, Ngarmukos, T, Fauchier, Laurent, Hatala, R, Halcox, J, Guerra, A, Grubb, N, Gray, H, Geanta, M, Frykman, V, Fay, M, Ezekowitz, M, Du, X, Doughty, R, Dixen, U, Davis, S, Crijns, H, Connolly, S, Christophersen, I, Chen, Sa, Chan, Ny, Caorsi, Wr, Bury, G, Breithardt, G, Berge, T, Al-Kalili, F, Al Awwad, A, Yan, Bryan, Wachter, Rolf, Verma, Atul, van Gelder, Isabelle, Uittenbogaart, Steven, Tveit, Arnljot, Turakhia, Mintu, Tieleman, Robert, Themistoclakis, Sakis, Svennberg, Emma, Svendsen, Jesper, Steinhubl, Steven, Siu, Chung-Wah, Schnabel, Renate, Sandhu, Roopinder, Rienstra, Michiel, Puererfellner, Helmut, Potpara, Tatjana, Poppe, Katrina, Piccini, Jonathan, Orchard, Jessica, Neubeck, Lis, Martinez, Carlos, Mairesse, Georges, Lowres, Nicole, Lobban, Trudie, Lip, Gregory, Levin, Lars-Åke, Lee, Vivian, Krieger, Derk, Kowey, Peter, Kirchhof, Paulus, Kamel, Hooman, Hills, Mellanie, Hillis, Graham, Harbison, Joseph, Hankey, Graeme, Gwynne, Kylie, Glotzer, Taya, Gladstone, David, Gersh, Bernard, Friberg, Leif, Fitzmaurice, David, Engdahl, Johan, Conen, David, Chao, Tze-Fan, Brandes, Axel, Brachmann, Johannes, Boriani, Giuseppe, Benjamin, Emelia, Antoniou, Sotiris, Wijeratne, T, Anderson, Craig, Walker, N, Albert, Christine, Verbiest van Gurp, N, Wang, Jiguang, Ushiyama, S, Rosenqvist, Mårten, Topol, E, Healey, Jeffrey, Takahashi, N, Calkins, Hugh, Suwanwela, N, Camm, John, Stewart, S, Freedman, Ben, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Éducation Éthique Santé EA 7505 (EES), Université de Tours (UT), EA4245 - Transplantation, Immunologie, Inflammation [Tours] (T2i), Service de Médecine Interne et Maladies Infectieuses [Tours], Service de Cardiologie (CHU Trousseau, Tours), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Cellules Dendritiques, Immunomodulation et Greffes, Service de Cardiologie B, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Johns Hopkins University (JHU), Centre for Epidemiological Studies and Clinical Trials, Shanghai Jiao Tong University School of Medicine-Ruijin Hospital, Black Mountain Laboratories, Commonwealth Scientific and Industrial Research Organisation [Canberra] (CSIRO), Biological and Environmental Sciences, University of Stirling, Boston University School of Medicine (BUSM), Boston University [Boston] (BU), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Coburg Hospital, and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
screening, atrial fibrillation, stroke, [SHS]Humanities and Social Sciences
Abstract

International audience; Approximately 10% of ischemic strokes are associated with atrial fibrillation (AF) first diagnosed at the time of stroke. Detecting asymptomatic AF would provide an opportunity to prevent these strokes by instituting appropriate anticoagulation. The AF-SCREEN international collaboration was formed in September 2015 to promote discussion and research about AF screening as a strategy to reduce stroke and death and to provide advocacy for implementation of country-specific AF screening programs. During 2016, 60 expert members of AF-SCREEN, including physicians, nurses, allied health professionals, health economists, and patient advocates, were invited to prepare sections of a draft document. In August 2016, 51 members met in Rome to discuss the draft document and consider the key points arising from it using a Delphi process. These key points emphasize that screen-detected AF found at a single timepoint or by intermittent ECG recordings over 2 weeks is not a benign condition and, with additional stroke factors, carries sufficient risk of stroke to justify consideration of anticoagulation. With regard to the methods of mass screening, handheld ECG devices have the advantage of providing a verifiable ECG trace that guidelines require for AF diagnosis and would therefore be preferred as screening tools. Certain patient groups, such as those with recent embolic stroke of uncertain source (ESUS), require more intensive monitoring for AF. Settings for screening include various venues in both the community and the clinic, but they must be linked to a pathway for appropriate diagnosis and management for screening to be effective. It is recognized that health resources vary widely between countries and health systems, so the setting for AF screening should be both country- and health system-specific. Based on current knowledge, this white paper provides a strong case for AF screening now while recognizing that large randomized outcomes studies would be helpful to strengthen the evidence base.

Published
2017
Full Text
View/download PDF

14. Screening for Atrial Fibrillation

Author

Freedman, Ben, primary, Camm, John, additional, Calkins, Hugh, additional, Healey, Jeffrey S., additional, Rosenqvist, Mårten, additional, Wang, Jiguang, additional, Albert, Christine M., additional, Anderson, Craig S., additional, Antoniou, Sotiris, additional, Benjamin, Emelia J., additional, Boriani, Giuseppe, additional, Brachmann, Johannes, additional, Brandes, Axel, additional, Chao, Tze-Fan, additional, Conen, David, additional, Engdahl, Johan, additional, Fauchier, Laurent, additional, Fitzmaurice, David A., additional, Friberg, Leif, additional, Gersh, Bernard J., additional, Gladstone, David J., additional, Glotzer, Taya V., additional, Gwynne, Kylie, additional, Hankey, Graeme J., additional, Harbison, Joseph, additional, Hillis, Graham S., additional, Hills, Mellanie T., additional, Kamel, Hooman, additional, Kirchhof, Paulus, additional, Kowey, Peter R., additional, Krieger, Derk, additional, Lee, Vivian W. Y., additional, Levin, Lars-Åke, additional, Lip, Gregory Y. H., additional, Lobban, Trudie, additional, Lowres, Nicole, additional, Mairesse, Georges H., additional, Martinez, Carlos, additional, Neubeck, Lis, additional, Orchard, Jessica, additional, Piccini, Jonathan P., additional, Poppe, Katrina, additional, Potpara, Tatjana S., additional, Puererfellner, Helmut, additional, Rienstra, Michiel, additional, Sandhu, Roopinder K., additional, Schnabel, Renate B., additional, Siu, Chung-Wah, additional, Steinhubl, Steven, additional, Svendsen, Jesper H., additional, Svennberg, Emma, additional, Themistoclakis, Sakis, additional, Tieleman, Robert G., additional, Turakhia, Mintu P., additional, Tveit, Arnljot, additional, Uittenbogaart, Steven B., additional, Van Gelder, Isabelle C., additional, Verma, Atul, additional, Wachter, Rolf, additional, Yan, Bryan P., additional, Al Awwad, A, additional, Al-Kalili, F, additional, Berge, T, additional, Breithardt, G, additional, Bury, G, additional, Caorsi, WR, additional, Chan, NY, additional, Chen, SA, additional, Christophersen, I, additional, Connolly, S, additional, Crijns, H, additional, Davis, S, additional, Dixen, U, additional, Doughty, R, additional, Du, X, additional, Ezekowitz, M, additional, Fay, M, additional, Frykman, V, additional, Geanta, M, additional, Gray, H, additional, Grubb, N, additional, Guerra, A, additional, Halcox, J, additional, Hatala, R, additional, Heidbuchel, H, additional, Jackson, R, additional, Johnson, L, additional, Kaab, S, additional, Keane, K, additional, Kim, YH, additional, Kollios, G, additional, Løchen, ML, additional, Ma, C, additional, Mant, J, additional, Martinek, M, additional, Marzona, I, additional, Matsumoto, K, additional, McManus, D, additional, Moran, P, additional, Naik, N, additional, Ngarmukos, T, additional, Prabhakaran, D, additional, Reidpath, D, additional, Ribeiro, A, additional, Rudd, A, additional, Savalieva, I, additional, Schilling, R, additional, Sinner, M, additional, Stewart, S, additional, Suwanwela, N, additional, Takahashi, N, additional, Topol, E, additional, Ushiyama, S, additional, Verbiest van Gurp, N, additional, Walker, N, additional, and Wijeratne, T, additional

Published
2017
Full Text
View/download PDF

15. Genetic loci associated with heart rate variability and their effects on cardiac disease risk

Author

Nolte, I. M. (Ilja M.), Munoz, M. L. (M. Loretto), Tragante, V. (Vinicius), Amare, A. T. (Azmeraw T.), Jansen, R. (Rick), Vaez, A. (Ahmad), von der Heyde, B. (Benedikt), Avery, C. L. (Christy L.), Bis, J. C. (Joshua C.), Dierckx, B. (Bram), van Dongen, J. (Jenny), Gogarten, S. M. (Stephanie M.), Goyette, P. (Philippe), Hernesniemi, J. (Jussi), Huikari, V. (Ville), Hwang, S.-J. (Shih-Jen), Jaju, D. (Deepali), Kerr, K. F. (Kathleen F.), Kluttig, A. (Alexander), Krijthe, B. P. (Bouwe P.), Kumar, J. (Jitender), van der Laan, S. W. (Sander W.), Lyytikäinen, L.-P. (Leo-Pekka), Maihofer, A. X. (Adam X.), Minassian, A. (Arpi), van der Most, P. J. (Peter J.), Mueller-Nurasyid, M. (Martina), Nivard, M. (Michel), Salvi, E. (Erika), Stewart, J. D. (James D.), Thayer, J. F. (Julian F.), Verweij, N. (Niek), Wong, A. (Andrew), Zabaneh, D. (Delilah), Zafarmand, M. H. (Mohammad H.), Abdellaoui, A. (Abdel), Albarwani, S. (Sulayma), Albert, C. (Christine), Alonso, A. (Alvaro), Ashar, F. (Foram), Auvinen, J. (Juha), Axelsson, T. (Tomas), Baker, D. G. (Dewleen G.), de Bakker, P. I. (Paul I. W.), Barcella, M. (Matteo), Bayoumi, R. (Riad), Bieringa, R. J. (Rob J.), Boomsma, D. (Dorret), Boucher, G. (Gabrielle), Britton, A. R. (Annie R.), Christophersen, I. E. (Ingrid E.), Dietrich, A. (Andrea), Ehret, G. B. (George B.), Ellinor, P. T. (Patrick T.), Eskola, M. (Markku), Felix, J. F. (Janine F.), Floras, J. S. (John S.), Franco, O. H. (Oscar H.), Friberg, P. (Peter), Gademan, M. G. (Maaike G. J.), Geyer, M. A. (Mark A.), Giedraitis, V. (Vilmantas), Hartman, C. A. (Catharina A.), Hemerich, D. (Daiane), Hofman, A. (Albert), Hottenga, J.-J. (Jouke-Jan), Huikuri, H. (Heikki), Hutri-Kähönen, N. (Nina), Jouven, X. (Xavier), Junttila, J. (Juhani), Juonala, M. (Markus), Kiviniemi, A. M. (Antti M.), Kors, J. A. (Jan A.), Kumari, M. (Meena), Kuznetsova, T. (Tatiana), Laurie, C. C. (Cathy C.), Lefrandt, J. D. (Joop D.), Li, Y. (Yong), Li, Y. (Yun), Liao, D. (Duanping), Limacher, M. C. (Marian C.), Lin, H. J. (Henry J.), Lindgren, C. M. (Cecilia M.), Lubitz, S. A. (Steven A.), Mahajan, A. (Anubha), McKnight, B. (Barbara), zu Schwabedissen, H. M. (Henriette Meyer), Milaneschi, Y. (Yuri), Mononen, N. (Nina), Morris, A. P. (Andrew P.), Nalls, M. A. (Mike A.), Navis, G. (Gerjan), Neijts, M. (Melanie), Nikus, K. (Kjell), North, K. E. (Kari E.), O'Connor, D. T. (Daniel T.), Ormel, J. (Johan), Perz, S. (Siegfried), Peters, A. (Annette), Psaty, B. M. (Bruce M.), Raitakari, O. T. (Olli T.), Risbrough, V. B. (Victoria B.), Sinner, M. F. (Moritz F.), Siscovick, D. (David), Smit, J. H. (Johannes H.), Smith, N. L. (Nicholas L.), Soliman, E. Z. (Elsayed Z.), Sotoodehnia, N. (Nona), Staessen, J. A. (Jan A.), Stein, P. K. (Phyllis K.), Stilp, A. M. (Adrienne M.), Stolarz-Skrzypek, K. (Katarzyna), Strauch, K. (Konstantin), Sundström, J. (Johan), Swenne, C. A. (Cees A.), Syvänen, A.-C. (Ann-Christine), Tardif, J.-C. (Jean-Claude), Taylor, K. D. (Kent D.), Teumer, A. (Alexander), Thornton, T. A. (Timothy A.), Tinker, L. E. (Lesley E.), Uitterlinden, A. G. (Andre G.), van Setten, J. (Jessica), Voss, A. (Andreas), Waldenberger, M. (Melanie), Wilhelmsen, K. C. (Kirk C.), Willemsen, G. (Gonneke), Wong, Q. (Quenna), Zhang, Z.-M. (Zhu-Ming), Zonderman, A. B. (Alan B.), Cusi, D. (Daniele), Evans, M. K. (Michele K.), Greiser, H. K. (Halina K.), van der Harst, P. (Pim), Hassan, M. (Mohammad), Ingelsson, E. (Erik), Järvelin, M.-R. (Marjo-Riitta), Kaab, S. (Stefan), Kähönen, M. (Mika), Kivimäki, M. (Mika), Kooperberg, C. (Charles), Kuh, D. (Diana), Lehtimäki, T. (Terho), Lind, L. (Lars), Nievergelt, C. M. (Caroline M.), O'Donnell, C. J. (Chris J.), Oldehinkel, A. J. (Albertine J.), Penninx, B. (Brenda), Reiner, A. P. (Alexander P.), Riese, H. (Harriette), van Roon, A. M. (Arie M.), Rioux, J. D. (John D.), Rotter, J. I. (Jerome I.), Sofer, T. (Tamar), Stricker, B. H. (Bruno H.), Tiemeier, H. (Henning), Vrijkotte, T. G. (Tanja G. M.), Asselbergs, F. W. (Folkert W.), Brundel, B. J. (Bianca J. J. M.), Heckbert, S. R. (Susan R.), Whitsel, E. A. (Eric A.), den Hoed, M. (Marcel), Snieder, H. (Harold), de Geus, E. J. (Eco J. C.), Nolte, I. M. (Ilja M.), Munoz, M. L. (M. Loretto), Tragante, V. (Vinicius), Amare, A. T. (Azmeraw T.), Jansen, R. (Rick), Vaez, A. (Ahmad), von der Heyde, B. (Benedikt), Avery, C. L. (Christy L.), Bis, J. C. (Joshua C.), Dierckx, B. (Bram), van Dongen, J. (Jenny), Gogarten, S. M. (Stephanie M.), Goyette, P. (Philippe), Hernesniemi, J. (Jussi), Huikari, V. (Ville), Hwang, S.-J. (Shih-Jen), Jaju, D. (Deepali), Kerr, K. F. (Kathleen F.), Kluttig, A. (Alexander), Krijthe, B. P. (Bouwe P.), Kumar, J. (Jitender), van der Laan, S. W. (Sander W.), Lyytikäinen, L.-P. (Leo-Pekka), Maihofer, A. X. (Adam X.), Minassian, A. (Arpi), van der Most, P. J. (Peter J.), Mueller-Nurasyid, M. (Martina), Nivard, M. (Michel), Salvi, E. (Erika), Stewart, J. D. (James D.), Thayer, J. F. (Julian F.), Verweij, N. (Niek), Wong, A. (Andrew), Zabaneh, D. (Delilah), Zafarmand, M. H. (Mohammad H.), Abdellaoui, A. (Abdel), Albarwani, S. (Sulayma), Albert, C. (Christine), Alonso, A. (Alvaro), Ashar, F. (Foram), Auvinen, J. (Juha), Axelsson, T. (Tomas), Baker, D. G. (Dewleen G.), de Bakker, P. I. (Paul I. W.), Barcella, M. (Matteo), Bayoumi, R. (Riad), Bieringa, R. J. (Rob J.), Boomsma, D. (Dorret), Boucher, G. (Gabrielle), Britton, A. R. (Annie R.), Christophersen, I. E. (Ingrid E.), Dietrich, A. (Andrea), Ehret, G. B. (George B.), Ellinor, P. T. (Patrick T.), Eskola, M. (Markku), Felix, J. F. (Janine F.), Floras, J. S. (John S.), Franco, O. H. (Oscar H.), Friberg, P. (Peter), Gademan, M. G. (Maaike G. J.), Geyer, M. A. (Mark A.), Giedraitis, V. (Vilmantas), Hartman, C. A. (Catharina A.), Hemerich, D. (Daiane), Hofman, A. (Albert), Hottenga, J.-J. (Jouke-Jan), Huikuri, H. (Heikki), Hutri-Kähönen, N. (Nina), Jouven, X. (Xavier), Junttila, J. (Juhani), Juonala, M. (Markus), Kiviniemi, A. M. (Antti M.), Kors, J. A. (Jan A.), Kumari, M. (Meena), Kuznetsova, T. (Tatiana), Laurie, C. C. (Cathy C.), Lefrandt, J. D. (Joop D.), Li, Y. (Yong), Li, Y. (Yun), Liao, D. (Duanping), Limacher, M. C. (Marian C.), Lin, H. J. (Henry J.), Lindgren, C. M. (Cecilia M.), Lubitz, S. A. (Steven A.), Mahajan, A. (Anubha), McKnight, B. (Barbara), zu Schwabedissen, H. M. (Henriette Meyer), Milaneschi, Y. (Yuri), Mononen, N. (Nina), Morris, A. P. (Andrew P.), Nalls, M. A. (Mike A.), Navis, G. (Gerjan), Neijts, M. (Melanie), Nikus, K. (Kjell), North, K. E. (Kari E.), O'Connor, D. T. (Daniel T.), Ormel, J. (Johan), Perz, S. (Siegfried), Peters, A. (Annette), Psaty, B. M. (Bruce M.), Raitakari, O. T. (Olli T.), Risbrough, V. B. (Victoria B.), Sinner, M. F. (Moritz F.), Siscovick, D. (David), Smit, J. H. (Johannes H.), Smith, N. L. (Nicholas L.), Soliman, E. Z. (Elsayed Z.), Sotoodehnia, N. (Nona), Staessen, J. A. (Jan A.), Stein, P. K. (Phyllis K.), Stilp, A. M. (Adrienne M.), Stolarz-Skrzypek, K. (Katarzyna), Strauch, K. (Konstantin), Sundström, J. (Johan), Swenne, C. A. (Cees A.), Syvänen, A.-C. (Ann-Christine), Tardif, J.-C. (Jean-Claude), Taylor, K. D. (Kent D.), Teumer, A. (Alexander), Thornton, T. A. (Timothy A.), Tinker, L. E. (Lesley E.), Uitterlinden, A. G. (Andre G.), van Setten, J. (Jessica), Voss, A. (Andreas), Waldenberger, M. (Melanie), Wilhelmsen, K. C. (Kirk C.), Willemsen, G. (Gonneke), Wong, Q. (Quenna), Zhang, Z.-M. (Zhu-Ming), Zonderman, A. B. (Alan B.), Cusi, D. (Daniele), Evans, M. K. (Michele K.), Greiser, H. K. (Halina K.), van der Harst, P. (Pim), Hassan, M. (Mohammad), Ingelsson, E. (Erik), Järvelin, M.-R. (Marjo-Riitta), Kaab, S. (Stefan), Kähönen, M. (Mika), Kivimäki, M. (Mika), Kooperberg, C. (Charles), Kuh, D. (Diana), Lehtimäki, T. (Terho), Lind, L. (Lars), Nievergelt, C. M. (Caroline M.), O'Donnell, C. J. (Chris J.), Oldehinkel, A. J. (Albertine J.), Penninx, B. (Brenda), Reiner, A. P. (Alexander P.), Riese, H. (Harriette), van Roon, A. M. (Arie M.), Rioux, J. D. (John D.), Rotter, J. I. (Jerome I.), Sofer, T. (Tamar), Stricker, B. H. (Bruno H.), Tiemeier, H. (Henning), Vrijkotte, T. G. (Tanja G. M.), Asselbergs, F. W. (Folkert W.), Brundel, B. J. (Bianca J. J. M.), Heckbert, S. R. (Susan R.), Whitsel, E. A. (Eric A.), den Hoed, M. (Marcel), Snieder, H. (Harold), and de Geus, E. J. (Eco J. C.)

Abstract

Reduced cardiac vagal control reflected in low heart rate variability (HRV) is associated with greater risks for cardiac morbidity and mortality. In two-stage meta-analyses of genome-wide association studies for three HRV traits in up to 53,174 individuals of European ancestry, we detect 17 genome-wide significant SNPs in eight loci. HRV SNPs tag non-synonymous SNPs (in NDUFA11 and KIAA1755), expression quantitative trait loci (eQTLs) (influencing GNG11, RGS6 and NEO1), or are located in genes preferentially expressed in the sinoatrial node (GNG11, RGS6 and HCN4). Genetic risk scores account for 0.9 to 2.6% of the HRV variance. Significant genetic correlation is found for HRV with heart rate (-0.74

Published
2017

17. Screening for Atrial Fibrillation

Author

Freedman, Ben, Camm, John, Calkins, Hugh, Healey, Jeffrey S., Rosenqvist, Mårten, Wang, Jiguang, Albert, Christine M., Anderson, Craig S., Antoniou, Sotiris, Benjamin, Emelia J., Boriani, Giuseppe, Brachmann, Johannes, Brandes, Axel, Chao, Tze-Fan, Conen, David, Engdahl, Johan, Fauchier, Laurent, Fitzmaurice, David A., Friberg, Leif, Gersh, Bernard J., Gladstone, David J., Glotzer, Taya V., Gwynne, Kylie, Hankey, Graeme J., Harbison, Joseph, Hillis, Graham S., Hills, Mellanie T., Kamel, Hooman, Kirchhof, Paulus, Kowey, Peter R., Krieger, Derk, Lee, Vivian W. Y., Levin, Lars-Åke, Lip, Gregory Y. H., Lobban, Trudie, Lowres, Nicole, Mairesse, Georges H., Martinez, Carlos, Neubeck, Lis, Orchard, Jessica, Piccini, Jonathan P., Poppe, Katrina, Potpara, Tatjana S., Puererfellner, Helmut, Rienstra, Michiel, Sandhu, Roopinder K., Schnabel, Renate B., Siu, Chung-Wah, Steinhubl, Steven, Svendsen, Jesper H., Svennberg, Emma, Themistoclakis, Sakis, Tieleman, Robert G., Turakhia, Mintu P., Tveit, Arnljot, Uittenbogaart, Steven B., Van Gelder, Isabelle C., Verma, Atul, Wachter, Rolf, Yan, Bryan P., Al Awwad, A, Al-Kalili, F, Berge, T, Breithardt, G, Bury, G, Caorsi, WR, Chan, NY, Chen, SA, Christophersen, I, Connolly, S, Crijns, H, Davis, S, Dixen, U, Doughty, R, Du, X, Ezekowitz, M, Fay, M, Frykman, V, Geanta, M, Gray, H, Grubb, N, Guerra, A, Halcox, J, Hatala, R, Heidbuchel, H, Jackson, R, Johnson, L, Kaab, S, Keane, K, Kim, YH, Kollios, G, Løchen, ML, Ma, C, Mant, J, Martinek, M, Marzona, I, Matsumoto, K, McManus, D, Moran, P, Naik, N, Ngarmukos, T, Prabhakaran, D, Reidpath, D, Ribeiro, A, Rudd, A, Savalieva, I, Schilling, R, Sinner, M, Stewart, S, Suwanwela, N, Takahashi, N, Topol, E, Ushiyama, S, Verbiest van Gurp, N, Walker, N, and Wijeratne, T

Full Text
View/download PDF

18. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients

Author

von der Maase, H, Rørth, M, Walbom-Jørgensen, S, Sørensen, B L, Christophersen, I S, Hald, T, Jacobsen, G K, Berthelsen, J G, Skakkebaek, N E, von der Maase, H, Rørth, M, Walbom-Jørgensen, S, Sørensen, B L, Christophersen, I S, Hald, T, Jacobsen, G K, Berthelsen, J G, and Skakkebaek, N E

Abstract

Udgivelsesdato: 1986-Nov-29, Carcinoma in situ in the contralateral testis was diagnosed in 27 of 500 patients (5.4%) with unilateral testicular germ cell cancer. Eight of the 27 patients received intensive chemotherapy for spread of their initial testicular cancer. Follow up biopsy studies did not detect changes of carcinoma in situ in any of these patients, and none developed a contralateral testicular tumour (observation time 12-88 months). Of the remaining 19 patients with carcinoma in situ, seven developed contralateral testicular cancer. The estimated risk of developing invasive growth was 40% within three years and 50% within five years. None of the 473 patients without carcinoma in situ detected by screening biopsy developed contralateral testicular cancer (observation time 12-96 months). No serious complications arose from the biopsy procedures. All patients with unilateral testicular germ cell cancer should be offered biopsy of the contralateral testis.

Published
1986

21. Publisher Correction: Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes (Nature Genetics, (2018), 50, 4, (524-537), 10.1038/s41588-018-0058-3)

Author

Malik, R., Chauhan, G., Traylor, M., Sargurupremraj, M., Okada, Y., Mishra, A., Rutten-Jacobs, L., Giese, A. -K, Laan, S. W., Gretarsdottir, S., Anderson, C. D., Chong, M., Adams, H. H. H., Ago, T., Almgren, P., Amouyel, P., Ay, H., Bartz, T. M., Benavente, O. R., Bevan, S., Boncoraglio, G. B., Brown, R. D., Butterworth, A. S., Carrera, C., Carty, C. L., Chasman, D. I., Chen, W. -M, Cole, J. W., Correa, A., Cotlarciuc, I., Cruchaga, C., Danesh, J., Bakker, P. I. W., Destefano, A. L., Den Hoed, M., Duan, Q., Engelter, S. T., Falcone, G. J., Gottesman, R. F., Grewal, R. P., Gudnason, V., Gustafsson, S., Haessler, J., Harris, T. B., Hassan, A., Havulinna, A. S., Heckbert, S. R., Holliday, E. G., Howard, G., Hsu, F. -C, Hyacinth, H. I., Ikram, M. A., Ingelsson, E., Irvin, M. R., Jian, X., Jiménez-Conde, J., Johnson, J. A., Jukema, J. W., Kanai, M., Keene, K. L., Kissela, B. M., Kleindorfer, D. O., Kooperberg, C., Kubo, M., Lange, L. A., Langefeld, C. D., Langenberg, C., Launer, L. J., Lee, J. -M, Lemmens, R., Leys, D., Lewis, C. M., Lin, W. -Y, Lindgren, A. G., Lorentzen, E., Magnusson, P. K., Maguire, J., Manichaikul, A., Mcardle, P. F., Meschia, J. F., Mitchell, B. D., Mosley, T. H., Nalls, M. A., Ninomiya, T., O’donnell, M. J., Psaty, B. M., Pulit, S. L., Rannikmäe, K., Reiner, A. P., Rexrode, K. M., Rice, K., Rich, S. S., Ridker, P. M., Rost, N. S., Rothwell, P. M., Rotter, J. I., Rundek, T., Sacco, R. L., Sakaue, S., Sale, M. M., Salomaa, V., Sapkota, B. R., Schmidt, R., Schmidt, C. O., Schminke, U., Sharma, P., Slowik, A., Sudlow, C. L. M., Tanislav, C., Tatlisumak, T., Taylor, K. D., Thijs, V. N. S., Thorleifsson, G., Thorsteinsdottir, U., Tiedt, S., Trompet, S., Tzourio, C., Duijn, C. M., Walters, M., Wareham, N. J., Wassertheil-Smoller, S., Wilson, J. G., Wiggins, K. L., Yang, Q., Yusuf, S., Bis, J. C., Pastinen, T., Ruusalepp, A., Schadt, E. E., Koplev, S., Björkegren, J. L. M., Codoni, V., Civelek, M., Smith, N. L., Trégouët, D. A., Christophersen, I. E., Roselli, C., Lubitz, S. A., Ellinor, P. T., Tai, E. S., Kooner, J. S., Kato, N., He, J., Harst, P., Elliott, P., Chambers, J. C., Takeuchi, F., Johnson, A. D., Amin, N., Aparicio, H. S., Arnett, D. K., Attia, J., Beiser, A. S., Berr, C., Buring, J. E., Bustamante, M., Caso, V., Cheng, Y. -C, Choi, S. H., Chowhan, A., Cullell, N., Dartigues, J. -F, Delavaran, H., Delgado, P., Dörr, M., Engström, G., Ford, I., Gurpreet, W. S., Hamsten, A., Heitsch, L., Hozawa, A., Ibanez, L., Ilinca, A., Ingelsson, M., Iwasaki, M., Jackson, R. D., Jood, K., Jousilahti, P., Kaffashian, S., Kalra, L., Kamouchi, M., Kitazono, T., Kjartansson, O., Kloss, M., Koudstaal, P. J., Krupinski, J., Labovitz, D. L., Laurie, C. C., Levi, C. R., Li, L., Lind, L., Lindgren, C. M., Lioutas, V., Liu, Y. M., Lopez, O. L., Makoto, H., Martinez-Majander, N., Matsuda, K., Minegishi, N., Montaner, J., Morris, A. P., Muiño, E., Müller-Nurasyid, M., Norrving, B., Ogishima, S., Parati, E. A., Peddareddygari, L. R., Pedersen, N. L., Pera, J., Perola, M., Pezzini, A., Pileggi, S., Rabionet, R., Riba-Llena, I., Ribasés, M., Romero, J. R., Roquer, J., Rudd, A. G., Sarin, A. -P, Sarju, R., Sarnowski, C., Sasaki, M., Satizabal, C. L., Satoh, M., Sattar, N., Sawada, N., Sibolt, G., Sigurdsson, Á, Smith, A., Sobue, K., Soriano-Tárraga, C., Stanne, T., Stine, O. C., Stott, D. J., Strauch, K., Takai, T., Tanaka, H., Tanno, K., Teumer, A., Tomppo, L., Nuria P Torres-Aguila, Touze, E., Tsugane, S., Uitterlinden, A. G., Valdimarsson, E. M., Lee, S. J., Völzke, H., Wakai, K., Weir, D., Williams, S. R., Wolfe, C. D. A., Wong, Q., Xu, H., Yamaji, T., Sanghera, D. K., Melander, O., Jern, C., Strbian, D., Fernandez-Cadenas, I., Longstreth, W. T., Rolfs, A., Hata, J., Woo, D., Rosand, J., Pare, G., Hopewell, J. C., Saleheen, D., Stefansson, K., Worrall, B. B., Kittner, S. J., Seshadri, S., Fornage, M., Markus, H. S., Howson, J. M. M., Kamatani, Y., Debette, S., and Dichgans, M.

22. Correspondence

Author

Theilade, K., primary, Munck-Hansen, J., additional, and Christophersen, I. Strøyer, additional

Published
1987
Full Text
View/download PDF

24. First three Escherichia coli isolates harbouring mcr-1 in Uruguay.

Author

Papa-Ezdra R, Grill Diaz F, Vieytes M, García-Fulgueiras V, Caiata L, Ávila P, Brasesco M, Christophersen I, Cordeiro NF, Algorta G, Galiana A, and Vignoli R

Subjects
Adult, Aged, 80 and over, Cephalosporins pharmacology, Colistin pharmacology, Escherichia coli drug effects, Escherichia coli genetics, Escherichia coli isolation & purification, Escherichia coli Infections blood, Escherichia coli Infections urine, Female, Gene Transfer, Horizontal, Humans, Male, Multilocus Sequence Typing, Rectum microbiology, Retrospective Studies, Uruguay epidemiology, Drug Resistance, Bacterial, Escherichia coli classification, Escherichia coli Infections microbiology, Escherichia coli Proteins genetics
Abstract

Objective: This report described the first Escherichia coli (E. coli) isolates harbouring mcr-1 in Uruguay., Methods: Three E. coli isolates were obtained from blood, urine and rectal swabs from different patients in two hospitals. Extended-spectrum β-lactamases (ESBL), plasmid-encoded (pAmpC) β-lactamases, plasmid-mediated quinolone resistance (PMQR) genes, class 1 integrons, and mcr-1, mcr-2 and mcr-3 were sought and characterised in three E. coli isolates. Transfer of resistance determinants was assessed by conjugation. Clonality was analysed by multilocus sequence typing., Results: All isolates were categorised as being colistin-resistant and the mcr-1 gene was detected. Two isolates were also resistant to oxyimino cephalosporins: one on account of bla CMY-2 and the other due to bla CTX-M-15 , the latter also harbouring transferable quinolone-resistance genes (aac(6')Ib-cr and qnrB). All mcr-1 genes were transferred by conjugation to recipient strains. The mcr-1-bearing isolates belonged to sequence types ST10, ST93 and ST5442., Conclusions: ST10 is considered as a high-risk clone worldwide. This type of mcr-1-harbouring clone is a major concern for human and animal health and must be under close surveillance. This study detected the presence of mcr-1 for the first time in Uruguay, albeit in an allodemic manner, associated with different antibiotic-resistance genes and from diverse clinical contexts. Considering that colistin is often the last therapeutic option available for multidrug-resistant Gram-negative bacilli infections, it is important to maximise precautions to avoid dissemination of isolates carrying mcr-1., (Copyright © 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights reserved.)

Published
2020
Full Text
View/download PDF

25. Erratum: Genetic loci associated with heart rate variability and their effects on cardiac disease risk.

Author

Nolte IM, Munoz ML, Tragante V, Amare AT, Jansen R, Vaez A, von der Heyde B, Avery CL, Bis JC, Dierckx B, van Dongen J, Gogarten SM, Goyette P, Hernesniemi J, Huikari V, Hwang SJ, Jaju D, Kerr KF, Kluttig A, Krijthe BP, Kumar J, van der Laan SW, Lyytikäinen LP, Maihofer AX, Minassian A, van der Most PJ, Müller-Nurasyid M, Nivard M, Salvi E, Stewart JD, Thayer JF, Verweij N, Wong A, Zabaneh D, Zafarmand MH, Abdellaoui A, Albarwani S, Albert C, Alonso A, Ashar F, Auvinen J, Axelsson T, Baker DG, de Bakker PIW, Barcella M, Bayoumi R, Bieringa RJ, Boomsma D, Boucher G, Britton AR, Christophersen I, Dietrich A, Ehret GB, Ellinor PT, Eskola M, Felix JF, Floras JS, Franco OH, Friberg P, Gademan MGJ, Geyer MA, Giedraitis V, Hartman CA, Hemerich D, Hofman A, Hottenga JJ, Huikuri H, Hutri-Kähönen N, Jouven X, Junttila J, Juonala M, Kiviniemi AM, Kors JA, Kumari M, Kuznetsova T, Laurie CC, Lefrandt JD, Li Y, Li Y, Liao D, Limacher MC, Lin HJ, Lindgren CM, Lubitz SA, Mahajan A, McKnight B, Zu Schwabedissen HM, Milaneschi Y, Mononen N, Morris AP, Nalls MA, Navis G, Neijts M, Nikus K, North KE, O'Connor DT, Ormel J, Perz S, Peters A, Psaty BM, Raitakari OT, Risbrough VB, Sinner MF, Siscovick D, Smit JH, Smith NL, Soliman EZ, Sotoodehnia N, Staessen JA, Stein PK, Stilp AM, Stolarz-Skrzypek K, Strauch K, Sundström J, Swenne CA, Syvänen AC, Tardif JC, Taylor KD, Teumer A, Thornton TA, Tinker LE, Uitterlinden AG, van Setten J, Voss A, Waldenberger M, Wilhelmsen KC, Willemsen G, Wong Q, Zhang ZM, Zonderman AB, Cusi D, Evans MK, Greiser HK, van der Harst P, Hassan M, Ingelsson E, Järvelin MR, Kääb S, Kähönen M, Kivimaki M, Kooperberg C, Kuh D, Lehtimäki T, Lind L, Nievergelt CM, O'Donnell CJ, Oldehinkel AJ, Penninx B, Reiner AP, Riese H, van Roon AM, Rioux JD, Rotter JI, Sofer T, Stricker BH, Tiemeier H, Vrijkotte TGM, Asselbergs FW, Brundel BJJM, Heckbert SR, Whitsel EA, den Hoed M, Snieder H, and de Geus EJC

Abstract

This corrects the article DOI: 10.1038/ncomms15805.

Published
2017
Full Text
View/download PDF

26. Genetic loci associated with heart rate variability and their effects on cardiac disease risk.

Author

Nolte IM, Munoz ML, Tragante V, Amare AT, Jansen R, Vaez A, von der Heyde B, Avery CL, Bis JC, Dierckx B, van Dongen J, Gogarten SM, Goyette P, Hernesniemi J, Huikari V, Hwang SJ, Jaju D, Kerr KF, Kluttig A, Krijthe BP, Kumar J, van der Laan SW, Lyytikäinen LP, Maihofer AX, Minassian A, van der Most PJ, Müller-Nurasyid M, Nivard M, Salvi E, Stewart JD, Thayer JF, Verweij N, Wong A, Zabaneh D, Zafarmand MH, Abdellaoui A, Albarwani S, Albert C, Alonso A, Ashar F, Auvinen J, Axelsson T, Baker DG, de Bakker PIW, Barcella M, Bayoumi R, Bieringa RJ, Boomsma D, Boucher G, Britton AR, Christophersen I, Dietrich A, Ehret GB, Ellinor PT, Eskola M, Felix JF, Floras JS, Franco OH, Friberg P, Gademan MGJ, Geyer MA, Giedraitis V, Hartman CA, Hemerich D, Hofman A, Hottenga JJ, Huikuri H, Hutri-Kähönen N, Jouven X, Junttila J, Juonala M, Kiviniemi AM, Kors JA, Kumari M, Kuznetsova T, Laurie CC, Lefrandt JD, Li Y, Li Y, Liao D, Limacher MC, Lin HJ, Lindgren CM, Lubitz SA, Mahajan A, McKnight B, Zu Schwabedissen HM, Milaneschi Y, Mononen N, Morris AP, Nalls MA, Navis G, Neijts M, Nikus K, North KE, O'Connor DT, Ormel J, Perz S, Peters A, Psaty BM, Raitakari OT, Risbrough VB, Sinner MF, Siscovick D, Smit JH, Smith NL, Soliman EZ, Sotoodehnia N, Staessen JA, Stein PK, Stilp AM, Stolarz-Skrzypek K, Strauch K, Sundström J, Swenne CA, Syvänen AC, Tardif JC, Taylor KD, Teumer A, Thornton TA, Tinker LE, Uitterlinden AG, van Setten J, Voss A, Waldenberger M, Wilhelmsen KC, Willemsen G, Wong Q, Zhang ZM, Zonderman AB, Cusi D, Evans MK, Greiser HK, van der Harst P, Hassan M, Ingelsson E, Järvelin MR, Kääb S, Kähönen M, Kivimaki M, Kooperberg C, Kuh D, Lehtimäki T, Lind L, Nievergelt CM, O'Donnell CJ, Oldehinkel AJ, Penninx B, Reiner AP, Riese H, van Roon AM, Rioux JD, Rotter JI, Sofer T, Stricker BH, Tiemeier H, Vrijkotte TGM, Asselbergs FW, Brundel BJJM, Heckbert SR, Whitsel EA, den Hoed M, Snieder H, and de Geus EJC

Subjects
Blood Pressure, Cohort Studies, Genetic Predisposition to Disease, Genome-Wide Association Study, Heart Diseases physiopathology, Humans, Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels genetics, Muscle Proteins genetics, Polymorphism, Single Nucleotide, Potassium Channels genetics, Quantitative Trait Loci, RGS Proteins genetics, Risk Factors, White People genetics, Heart Diseases genetics, Heart Rate
Abstract

Reduced cardiac vagal control reflected in low heart rate variability (HRV) is associated with greater risks for cardiac morbidity and mortality. In two-stage meta-analyses of genome-wide association studies for three HRV traits in up to 53,174 individuals of European ancestry, we detect 17 genome-wide significant SNPs in eight loci. HRV SNPs tag non-synonymous SNPs (in NDUFA11 and KIAA1755), expression quantitative trait loci (eQTLs) (influencing GNG11, RGS6 and NEO1), or are located in genes preferentially expressed in the sinoatrial node (GNG11, RGS6 and HCN4). Genetic risk scores account for 0.9 to 2.6% of the HRV variance. Significant genetic correlation is found for HRV with heart rate (-0.74g <-0.55) and blood pressure (-0.35g <-0.20). These findings provide clinically relevant biological insight into heritable variation in vagal heart rhythm regulation, with a key role for genetic variants (GNG11, RGS6) that influence G-protein heterotrimer action in GIRK-channel induced pacemaker membrane hyperpolarization.

Published
2017
Full Text
View/download PDF

27. Community-acquired methicillin-resistant Staphylococcus aureus, Uruguay.

Author

Ma XX, Galiana A, Pedreira W, Mowszowicz M, Christophersen I, Machiavello S, Lope L, Benaderet S, Buela F, Vincentino W, Albini M, Bertaux O, Constenla I, Bagnulo H, Llosa L, Ito T, and Hiramatsu K

Subjects
Adhesins, Bacterial genetics, Adult, Anti-Bacterial Agents pharmacology, Bacterial Toxins, Community-Acquired Infections microbiology, Community-Acquired Infections mortality, Exotoxins, Humans, Leukocidins genetics, Microbial Sensitivity Tests, Middle Aged, Staphylococcal Infections microbiology, Staphylococcal Infections mortality, Staphylococcus aureus genetics, Staphylococcus aureus pathogenicity, Uruguay epidemiology, Community-Acquired Infections epidemiology, Disease Outbreaks, Drug Resistance, Multiple, Bacterial genetics, Methicillin Resistance, Staphylococcal Infections epidemiology, Staphylococcus aureus drug effects
Abstract

A novel, methicillin-resistant [corrected] Staphylococcus aureus clone (Uruguay clone) with a non-multidrug-resistant phenotype caused a large outbreak, including 7 deaths, in Montevideo, Uruguay. The clone was distinct from the highly virulent community clone represented by strain MW2, although both clones carried Panton-Valentine leukocidin gene and cna gene.

Published
2005
Full Text
View/download PDF

28. [Patients with early stages of endometrial cancer should be spared adjuvant radiotherapy. Danish Endometrial Cancer Group].

Author

Poulsen HK, Jacobsen M, Bertelsen K, Andersen JE, Ahrons S, Bock JE, Bostofte E, Engelholm SA, Hølund B, Jakobsen AK, Kiaer H, Nyland MH, Pedersen PH, and Christophersen IS

Subjects
Adult, Aged, Carcinoma pathology, Carcinoma surgery, Denmark, Endometrial Neoplasms pathology, Endometrial Neoplasms surgery, Female, Follow-Up Studies, Humans, Hysterectomy, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Risk Factors, Carcinoma radiotherapy, Endometrial Neoplasms radiotherapy, Radiotherapy, Adjuvant
Abstract

In an attempt to create uniform nationwide guidelines for the management of all stages of endometrial carcinoma, and to limit the use of adjuvant radiation therapy in stage I disease to high-risk patients only, a protocol was developed by the Danish Endometrial Cancer group (DEMCA). From September 1986 through August 1988, 1214 women in Denmark with newly diagnosed carcinoma of the endometrium have been treated according to this protocol. This figure represents all endometrial carcinomas diagnosed in Denmark during this two-year period. The primary treatment was total abdominal hysterectomy and bilateral salpingo-oophorectomy, no preoperative radiation therapy was delivered. In 1039 cases no macroscopic residual tumour and/or microscopic tumor tissue in the resection margins was found following surgery. Based on surgery and histopathology, these patients were classified as: P-stage I low risk (n = 641), P-stage I high risk (n = 235), P-stage II (n = 105) and P-stage III, Group 1 (n = 58). No postoperative radiation therapy was given to P-I low risk cases. P-I high risk, P-II, and P-III (Group 1) cases received external radiation therapy. Recurrence rate at 68-92 months follow-up was 45/641 (7%) in P-I low risk, 36/235 (15%) in P-I high risk, 30/105 (29%) in P-II, and 27/58 (47%) in P-III (Group 1) cases. Fifteen of 17 vaginal recurrences in P-I low risk cases were salvaged (mean observation time 61 months). In this population-based investigation it has been shown that P-stage low-risk patients are adequately treated by total abdominal hysterectomy and bilateral salpingo-oophorectomy, and that no pre- or postoperative radiation therapy is necessary.

Published
1997

29. [Treatment of cervix cancer in Denmark].

Author

Jakobsen AK, Bertelsen K, Andreasson B, Bichel P, Christensen JJ, Christophersen IS, Engelholm SA, Havsteen H, Hjelm-Hansen M, and Jensen F

Subjects
Denmark epidemiology, Female, Humans, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms therapy
Abstract

The current status of cervical cancer treatment in Denmark is discussed. Diagnostic aspects and problems of classification are presented briefly supplemented with a comment on new prognostic parameters based on a semiquantitative score system and flow cytometry. Surgery is the treatment of election for the early stages whereas radiotherapy is the treatment of choice in advanced stages. Chemotherapy should only be employed in the framework of clinical trials. It is concluded that centralised treatment should be maintained.

Published
1991

30. Interferon therapy in neoplastic disease. A preliminary report.

Author

Christophersen IS, Jordal R, Osther K, Lindenberg J, Pedersen PH, and Berg K

Subjects
Adolescent, Adult, Aged, Antineoplastic Agents administration & dosage, Bone Neoplasms drug therapy, Child, Female, Humans, Interferons administration & dosage, Male, Middle Aged, Neoplasm Metastasis, Neoplasms surgery, Osteosarcoma drug therapy, Osteosarcoma therapy, Papilloma surgery, Papilloma therapy, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms surgery, Uterine Neoplasms radiotherapy, Uterine Neoplasms therapy, Interferons therapeutic use, Neoplasms drug therapy
Abstract

The treatment of 10 patients having neoplastic disease with exogenous i.m. interferon therapy is described. The interferon given is partially purified interferon produced from human leukocytes. Sendai virus is used as interferon inductor. The patients reported in this paper have been on treatment for periods of 2-28 months. Apart from initial periods of fever, no side-effects have been recorded. Patients suffering from bladder papillomas have shown partial regression after a few months of therapy. The other cases treated are too few to warrant any conclusions, but the therapy does seem to have been beneficial.

Published
1978
Full Text
View/download PDF

31. Phase II study of adriamycin, 5-fluorouracil, levamisole, and irradiation in carcinoma of the bladder.

Author

Lundbeck F and Christophersen IS

Subjects
Bone Marrow drug effects, Carcinoma, Transitional Cell therapy, Doxorubicin adverse effects, Drug Evaluation, Drug Therapy, Combination, Fluorouracil adverse effects, Humans, Levamisole adverse effects, Nausea chemically induced, Remission, Spontaneous, Doxorubicin administration & dosage, Fluorouracil administration & dosage, Levamisole administration & dosage, Urinary Bladder Neoplasms therapy
Abstract

Since July 1976, 19 patients with carcinoma of the bladder have been treated with adriamycin, 5-fluorouracil, and levamisole combined with radiotherapy (60 Gy [6000 radsA1/24 fractions/6 weeks). Chemotherapy and radiotherapy were initiated simultaneously, with the entire treatment lasting 7--8 months. Three months after the completion of radiotherapy, 14 of the 18 patients in whom cystoscopy was performed were found to be in complete remission. Overall, 17 of the 19 patients have responded to the treatment and 15 patients have at some time shown complete remission. The toxic effects seen were myelosuppression, nausea, vomiting, diarrhea, loss of weight, and alopecia. Thirteen patients received the entire treatment as outpatients while six patients had to be hospitalized for a period of 8--14 days because of severe side effects, especially in Weeks 3--8. Serious complications such as bowel perforation were not seen, but one patient died with septicemia as a result of agranulocytosis, which was attributed to the treatment with levamisole.

Published
1979

32. Intravesical therapy of noninvasive bladder tumors (stage Ta) with doxorubicin: initial treatment results and the long-term course.

Author

Lundbeck F, Bruun E, Finnerup B, and Christophersen IS

Subjects
Administration, Intravesical, Adult, Aged, Aged, 80 and over, Doxorubicin administration & dosage, Follow-Up Studies, Humans, Middle Aged, Time Factors, Doxorubicin therapeutic use, Neoplasm Recurrence, Local, Urinary Bladder Neoplasms drug therapy
Abstract

A total of 64 consecutive patients with noninvasive bladder tumors (stage Ta) between 1977 and 1983 underwent treatment with intravesical instillation of doxorubicin. The total response rate was 85 per cent and 57 per cent of the patients had a complete response after 16 weekly instillations. Half of the patients with a complete response had recurrences within 12 to 16 months. Ten per cent of all patients had an invasive tumor during the observation period. We conclude that doxorubicin can render some patients with noninvasive bladder tumors (stage Ta) free of disease but there currently is nothing to indicate that the same results could not be obtained by transurethral resection.

Published
1988
Full Text
View/download PDF

33. [Various prognostic factors in breast cancer].

Author

Christophersen IS, Sveinsson T, and Rygård J

Subjects
Breast pathology, Breast Neoplasms mortality, Breast Neoplasms pathology, Female, Humans, Lymphatic Metastasis, Prognosis, Breast Neoplasms diagnosis
Published
1977

34. [Nosocomial outbreak of Proteus penneri infections at a general hospital].

Author

Christophersen I, Galiana A, López L, González S, Bazet C, and Pedreira W

Subjects
Hospital Departments, Hospitals, General, Humans, Sepsis epidemiology, Urinary Tract Infections epidemiology, Uruguay epidemiology, Cross Infection epidemiology, Disease Outbreaks, Proteus Infections epidemiology
Published
1989

35. Interferon therapy in recurrent renal carcinoma.

Author

Magnusson K, Christophersen IS, Jordal R, Holm HH, and Mygind T

Subjects
Adult, Female, Humans, Leukocytes immunology, Male, Middle Aged, Adenocarcinoma therapy, Interferons therapeutic use, Kidney Neoplasms therapy, Neoplasm Recurrence, Local therapy
Abstract

Seven patients with recurrent renal carcinoma, who had previously been treated with progesterone and vinblastine for progressive disease, were treated with human leukocyte interferon (HuIFN alpha). Five patients received daily escalating i.m. IFN doses from 4 X 10 up to 16 X 10(6) U during a minimum of 4 weeks, while two patients received intralesional IFN, 20 X 10(6) U/dose. No serious side-effects were observed. No tumor response was found in any of these patients.

Published
1983
Full Text
View/download PDF

37. Carcinoma-in-situ of testis eradicated by chemotherapy.

Author

von der Maase H, Berthelsen JG, Jacobsen GK, Hald T, Rørth M, Christophersen IS, Sørensen BL, Walbom-Jørgensen S, and Skakkebaek NE

Subjects
Humans, Male, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma in Situ drug therapy, Testicular Neoplasms drug therapy
Published
1985
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results